Il25 and Il23 on Diabetic Mice | ||
| Egyptian Society of Diabetes and Lipidology Journal | ||
| Volume 2, Issue 1, April 2022 PDF (66.59 K) | ||
| Document Type: Abstracts | ||
| DOI: 10.21608/esdlj.2022.455711 | ||
| Abstract | ||
| Type 1 diabetes (T1D) is a complex chronic autoimmune inflammatory disease in which induced cytokine production creates dynamic environments for evolution and activity of effector as well as regulatory cells. Low-dose IL-2 has been applied for the treatment of recent-onset T1D in NOD mice. Different IL-2 formulations, for instance, nanoparticle encapsulation, have been implicated to improve the therapeutic utility of low-dose IL-2 to achieve precise suppression of pathological immune responses. | ||
|
Statistics Article View: 22 PDF Download: 9 |
||
